New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
09:15 EDTADMP, KSU, IGT, BDSI, ISRG, SBUX, GWW, PTCT, XRX, KMB, MSFT, FEYE, ENDP, SWK, JNPROn The Fly: Pre-market Movers
UP AFTER EARNINGS: Microsoft (MSFT), up 3.5%... Starbucks (SBUX), up 1.2%... Juniper (JNPR), up 5.4%... Kimberly Clark (KMB), up 2%... Stanley Black & Decker (SWK), up 1%. ALSO HIGHER: BioDelivery (BDSI), up 43% after announcing positive top-line results from BEMA Phase III trial with Endo (ENDP) unit... Adamis (ADMP), up 6% after receiving Notice of Allowance of patent claims for immunotherapy portfolio. DOWN AFTER EARNINGS: International Game (IGT), down 11%... Intuitive Surgical (ISRG), down 5.5%... Xerox (XRX), down 2.6%... W.W. Grainger (GWW). down 4.5%... Kansas City Southern (KSU), down 8%. ALSO LOWER: PTC Therapeutics (PTCT), down 18% after announcing EMA adopted negative opinion on MAA for Atuluren approval... FireEye (FEYE), down 2.4% following downgrade at Barclays.
News For MSFT;SBUX;JNPR;KMB;ISRG;SWK;XRX;BDSI;ENDP;PTCT;IGT;FEYE;GWW;KSU;ADMP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
December 10, 2014
08:16 EDTFEYE, JNPRBarclays to hold a conference
Global Technology Conference is being held in San Francisco on December 9-10 with webcasted company presentations to begin on December 10 at 10:40 am; not all company presentations may be webcasted.Webcast Link
07:24 EDTSWKImperial Capital to hold a conference
Subscribe for More Information
December 9, 2014
12:15 EDTPTCTPTC Therapeutics mentioned positively by dealReporter
Subscribe for More Information
10:23 EDTJNPROn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:22 EDTJNPRBMO Capital to hold a conference
Subscribe for More Information
07:08 EDTENDPEndo completes acquisition of rights to Natesto from Trimel BioPharma
Endo International announced the completion of the acquisition of rights to Natesto, a testosterone nasal gel, the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma, a wholly-owned subsidiary of Trimel Pharmaceuticals for $25M including additional payments upon the achievement of certain regulatory and sales milestones. Endo will collaborate with Trimel on all regulatory and clinical development activities regarding Natesto. Endo intends to launch the product, through its Endo Pharmaceuticals subsidiary, in the Q1 of 2015.
06:39 EDTJNPRJuniper initiated with a Neutral at Wedbush
Subscribe for More Information
06:27 EDTMSFTSamsung, white-box makers to benefit from Microsoft Mobile exit, DigiTimes says
Subscribe for More Information
06:08 EDTFEYEFireEye announces partnership with Deutsche Telekom
Subscribe for More Information
December 8, 2014
13:21 EDTMSFTMicrosoft files appeal in case on customer data in Ireland
Microsoft said on its blog that it has filed an appeal in its ongoing case challenging a U.S. government search warrant for customer data stored in Ireland. Microsoft said it filed the appeal after a U.S. district court judge rejected the company’s argument that the warrant is illegal because it calls for the seizure of emails stored outside the United States. Reference Link
12:40 EDTMSFTOn The Fly: Midday Wrap
Subscribe for More Information
10:44 EDTMSFTDigital River grants Microsoft extestion to decide on renewing pact
Subscribe for More Information
10:04 EDTMSFTAccenture and Microsoft launch hybrid cloud platform
Subscribe for More Information
09:54 EDTFEYEFireEye calls active on renewed takeover chatter
FireEye December 31 and January 33 calls are active on 6300 contracts (800 puts) on renewed takeover chatter. December weekly call option implied volatility is at 67, December is at 53 compared to its 26-week average of 57 according to Track Data. Active call volume suggests traders taking positions for upside price movement.
09:40 EDTFEYERumor: FireEye moves up on renewed takeover chatter
Subscribe for More Information
09:32 EDTENDPSyneron Medical signs agreement with AMS to supply holmium laser for urology
Subscribe for More Information
07:52 EDTSBUXStarbucks price target raised to $97 from $88 at Jefferies
Subscribe for More Information
07:28 EDTFEYEFBN Securities to hold a bus tour
Subscribe for More Information
07:01 EDTBDSIBioDelivery Sciences completes randomization in trial of clonidine topical gel
BioDelivery Sciences announced that it has completed the randomization of all patients in BDSI's ongoing initial pivotal Phase 3 clinical trial for Clonidine Topical Gel for the treatment of painful diabetic neuropathy. BDSI anticipates that topline results of the study will be available by the end of March 2015. The Phase 3 trial is a multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of Clonidine Topical Gel in the treatment of pain associated with PDN. In the trial, known as the RHAPSODY Study, subjects were randomized to receive either Clonidine Topical Gel or a placebo gel. Two hundred and sixty three adult subjects were randomized into the 12 week double-blind treatment phase of the study. This is the first of two pivotal trials that would be required for submission of a New Drug Application to the U.S. Food and Drug Administration. FDA has granted Fast Track designation for the program, which recognizes the need of developing new therapies for this serious condition. BDSI plans to begin the second Phase 3 study during the first quarter of 2015.
06:47 EDTSBUXStarbucks coverage resumed with a Conviction Buy at Goldman
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use